Latest Transplant rejection Stories
Avoiding kidney mismatching is beneficial in pediatric kidney transplant patients, however, the likelihood of finding a matching donor must be considered against the wait time for a possible donation, according to this study.
Avoiding HLA-DR mismatching appears to be beneficial in pediatric kidney transplant patients, however the likelihood of finding a matching donor must be considered against the wait time for a possible donation.
EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking AfinitorÂ® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6).
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans.
SILVER SPRING, Md., June 15, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Nulojix (belatacept) to prevent acute rejection in adult patients who have had a kidney transplant.
Cells found naturally in the body may help prevent the rejection of an organ transplant. Research shows new cell therapy could also eliminate a transplant patientâ€™s need for life-long medication and could help their transplant last longer.
In the first head-to-head comparison of the three most common drugs used at the time of a kidney transplant to prevent organ rejection, researchers found that the least expensive drug â€“ at one-half to one-fifth the price â€“ is as safe and effective as the other two.
University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells â€“ also known as "suppressor cells."
Researchers at King's College London have used cells found naturally in the body, to re-educate the immune system to prevent rejection of an organ transplant while remaining capable of fighting infections and cancer.
DURHAM, N.C., May 4, 2011 /PRNewswire/ -- Argos Therapeutics today announced that its immunotherapy platform based on recombinant human soluble CD83 demonstrated significant promise for renal and heart transplantation.
- A woman chauffeur.
- A woman who operates an automobile.